FDA: Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability
Notice from the Food and Drug Administration (FDA) announcing the revocation of one Emergency Use Authorization (EUA) issued to Eli Lilly and Co. (Lilly) for bamlanivimab and etesevimab administered together. The revocation is effective December 14, 2023.
Source: Federal Register updates via the Rural Assistance Center - Category: Rural Health Source Type: news
More News: COVID-19 | Emergency Medicine | Food and Drug Administration (FDA) | Pandemics | Rural Health